Schizophrenia and sickle cell drugs, D.C. update: a BioCentury podcast

A first-in-class approval for BMS. A Pfizer withdrawal. ODAC & PD-L1. Congress’ unfinished business. BioAge’s NASDAQ IPO

Approval of BMS’s first-in-class schizophrenia drug is good news for patients and the company’s thinning pipeline alike, but maximizing Cobenfy’s commercial potential depends on readouts in additional indications. On the latest BioCentury This Week podcast, BioCentury’s editors assess the significance of the new therapy from Bristol Myers Squibb Co. (NYSE:BMY) and what the pharma needs to do to make its launch a success.

They also discuss the impact of the withdrawal of a sickle cell therapy from  Pfizer Inc. (NYSE:PFE) on patients worldwide; the work left unfinished on biotech-related legislation in Congress; and the NASDAQ IPO of BioAge Labs Inc. (NASDAQ:BIOA).

Additionally, they explain the importance of FDA’s Oncologic Drugs Advisory Committee (ODAC) meeting on the use of PD-1 inhibitors in patients with certain tumors expressing low levels of PD-L1, including comments by Richard Pazdur, director of FDA’s Oncology Center of Excellence.

This episode of BioCentury This Week was sponsored by Parexel Biotech. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com. To submit a question to BioCentury’s editors, email the team at podcasts@biocentury.com.